Spyre Therapeutics (SYRE) Free Cash Flow (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Free Cash Flow came in at -$57.4 million in Q1 2026, down 39.95% YoY from -$95.5 million in Q1 2025, and down 28.7% on a QoQ basis from -$44.6 million in Q4 2025.
Spyre Therapeutics (SYRE) Free Cash Flow (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Free Cash Flow data on file, last reported at -$57.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 39.95% year-over-year to -$57.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$185.6 million (down 9.28% YoY) and the FY2025 annual result came in at -$169.3 million, down 7.52% from the prior year.
- Free Cash Flow eased to -$57.4 million in Q1 2026, from -$44.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$15.1 million in Q3 2022 to a low of -$62.2 million in Q2 2024.
- A 5-year average of -$33.1 million and a median of -$31.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 1107.46% — and 2023, when it jumped 32.95%.
- Tracing SYRE's Free Cash Flow over 5 years: stood at -$18.1 million in 2022, then slumped by 71.09% to -$31.0 million in 2023, then decreased by 19.86% to -$37.2 million in 2024, then retreated by 19.84% to -$44.6 million in 2025, then declined by 28.7% to -$57.4 million in 2026.
- The last three Free Cash Flow figures came in at -$57.4 million (Q1 2026), -$44.6 million (Q4 2025), and -$37.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | -69.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.88 Mn |
| Jun 30, 2026 | -69.88 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Mar 31, 2024 | -28.54 Mn |
| Mar 31, 2024 | -28.54 Mn |